METHOD FOR PREVENTION OF ALLOGENIC BONE MARROW OR HAEMOPOIETIC STEM CELL TRANSPLANT FAILURE IN PRESENCE OF DONOR-SPECIFIC ANTI-HLA ANTIBODIES IN RECIPIENT Russian patent published in 2025 - IPC A61K31/5377 A61K39/395 A61P37/06 

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine, namely to transplantology, and can be used for the prevention of allogenic bone marrow transplant failure or hematopoietic stem cells in the presence of donor-specific anti-HLA antibodies in the recipient. Method involves a single infusion of an anti-CD20 monoclonal antibody, oral administration of an inosine monophosphate dehydrogenase inhibitor and performing two plasmapheresis in recipients with a blood system disease in the presence of donor-specific antibodies (DSA) with an mean fluorescence intensity (MFI) greater than 5000. Anti-CD20 monoclonal antibody is an antibody that binds to the CD20 receptor on B cells and initiates cell lysis, as a result of which plasma cells are not formed, wherein said infusion is performed 15 days before the introduction of the allogenic bone marrow or HSC to the recipient. Inosine monophosphate dehydrogenase inhibitor is a lymphostatic preparation with a function of inhibiting proliferation of B-lymphocytes and blocking formation of DSA by these cells, wherein said intake is carried out from 2nd week to transplantation of allogenic bone marrow or hematopoietic stem cells (allo-HSCT) in a continuous mode for up to 3 months after introduction of cells into recipient of allogenic bone marrow or HSC. Plasmapheresis is performed at least 1 volume of circulating blood each, per day and on the day of introduction of allogenic bone marrow or HSC.

EFFECT: use of the invention enables to achieve the elimination or significant reduction of the level of anti-HLA antibodies to permissible values - less than 5000 MFI in the blood serum of the recipient of the HSC by the day of the allogenic bone marrow or HSC transplantation, due to the complex action, manifested by the destruction of the antibody-synthesizing B-cells, inhibition of antibody production by the remaining B-cells, mechanical removal of DSA by plasmapheresis and binding of the DSA by phenotype-matched platelet concentrates, thereby reducing the risk of developing graft failure, allergic reactions, increasing the effectiveness of treatment and reducing the length of patient’s follow-up in a hospital environment.

4 cl, 1 dwg, 1 tbl, 4 ex